Filing Flows

Filing Flows › Health Care › Nu Skin Enterprises (NUS)

Nu Skin Enterprises (NUS) earnings and revenue breakdown

Latest: Q3 2026 · 10-Q filed Nov 6, 2026 · Nu Skin Enterprises (NUS) Q3 2026 earnings results →

Q3 2026 Revenue down 15% year over year to $311M · 0¢ of every $1 of revenue lost · operating margin 1.6%

Nu Skin Enterprises made $311M in Q3 2026 (-15% Y/Y). Operating margin 1.6%, net loss $742K. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 6, 2026.

Revenue$311M
Year over year-15%
Operating margin1.6%
Net earnings−$742K
Operating cash flow−$8.1M

Drawing the Sankey…

Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF

What changed this quarter

Revenue was $311.0M in Q3 2026, down 15% year over year and down 3% from the previous quarter.

Gross margin was 65.0%, down 5.5 points from Q3 2025. Operating profit was $5.1M, a 1.6% margin (down 4.3 points year over year). Operating expenses fell 16% while revenue fell 15%. The quarter ended with a net loss of $742K, narrower than the previous quarter's $249.8M loss. Net interest and other expense of $3.2M was the main reason.

Operating cash flow was −$8.1M. Non-cash charges added back $12.5M of depreciation and amortization and $2.7M of share-based compensation. Working capital and other items used $22.6M. Capital expenditures of $11.3M exceeded it, leaving free cash flow of −$19.5M.

Quarterly history

Nu Skin Enterprises revenue by quarterNu Skin Enterprises revenue by quarter$364MQ1 2025$386MQ2 2025$364MQ3 2025$370MQ4 2025$321MQ1 2026$320MQ2 2026$311MQ3 2026
Nu Skin Enterprises net earnings by quarterNu Skin Enterprises net earnings by quarter$108MQ1 2025$21.1MQ2 2025$17.1MQ3 2025$14.5MQ4 2025$1.8MQ1 2026−$250MQ2 2026−$742KQ3 2026
QuarterFormFiledRevenueY/YOp. marginNet earningsOp. cash flow
Q3 202610-QNov 6, 2026$311M-15%1.6%−$742K−$8.1M
Q2 202610-QAug 10, 2026$320M-17%-18.5%−$250M$10.6M
Q1 202610-QMay 8, 2026$321M-12%1.3%$1.8M−$3.9M
Q4 202510-KFeb 13, 2026$370M-17%6.3%$14.5M$16.6M
Q3 202510-QNov 7, 2025$364M-15%5.9%$17.1M$27.5M
Q2 202510-QAug 8, 2025$386M-12%8.0%$21.1M$35.8M
Q1 202510-QMay 9, 2025$364M-13%-2.7%$108M$389K

Charts

Nu Skin Enterprises: revenue growth, year over year and quarter over quarterNu Skin Enterprises: revenue growth, year over year and quarter over quarterY/YQ/Q-13%Q1 2025-12%+6%Q2 2025-15%-6%Q3 2025-17%+2%Q4 2025-12%-13%Q1 2026-17%0%Q2 2026-15%-3%Q3 2026
Latest (Q3 2026): Y/Y -15%, Q/Q -3%.
Nu Skin Enterprises: where the cash came from (+) and went (−), TTM to Q3 2026Nu Skin Enterprises: where the cash came from (+) and went (−), TTM to Q3 2026Cash drawn (+) / kept (−)$86.9MCapital spending−$41.5MNet borrowing (+) / repaid (−)−$27.0MOperating cash flow$15.2MBuybacks−$15.0MOther financing−$12.1MDividends−$11.6MOther investing$6.6MExchange rates−$1.5M
From the cash-flow statement as filed (SEC XBRL). Cash is fungible: the bars do not say which dollar paid for what.
Nu Skin Enterprises: profit against cash, quarter by quarterNu Skin Enterprises: profit against cash, quarter by quarterNet incomeOperating cash flow−$36.1M$25.8MQ4 2024$108M$389KQ1 2025$21.1M$35.8MQ2 2025$17.1M$27.5MQ3 2025$14.5M$16.6MQ4 2025$1.8M−$3.9MQ1 2026−$250M$10.6MQ2 2026−$742K−$8.1MQ3 2026
Latest (Q3 2026): Net income −$742K, Operating cash flow −$8.1M.
Nu Skin Enterprises: diluted shares by fiscal yearNu Skin Enterprises: diluted shares by fiscal year53MFY202051MFY202151MFY202250MFY202350MFY202450MFY2025
-4.7% since FY2020: buybacks shrank the count.
Nu Skin Enterprises: long-term debt falling due (FY2025)Nu Skin Enterprises: long-term debt falling due (FY2025)$20.0M2026$205M2027
Cash $239M, short-term investments $1.2M, long-term debt — at 2025-12-31.
Nu Skin Enterprises in its industry: growth against margin (9 companies, SIC 5122)Nu Skin Enterprises in its industry: growth against margin (9 companies, SIC 5122)revenue growth, year over year →↑ operating marginmedian +5%median 1%MCKCORCAHHLFCOSMMEDSSTEKESYNNUS (-15%, 2%)
Wholesale-Drugs, Proprietaries & Druggists' Sundries; dot size is quarterly revenue; dashed lines are the industry's medians.

Interactive views

The same charts as the app — open one to draw it.

💵Where each $1 goesinteractive

Loading the interactive chart…

🌏Named in Asian annual reportsinteractive

Loading the interactive chart…

🔄Rotation against the market and its industry (RRG)interactive

Loading the interactive chart…

🔍Earnings qualityinteractive

Loading the interactive chart…

⚖️Fair value by methodinteractive

Loading the interactive chart…

🔭Outlook & guidanceinteractive

Loading the interactive chart…

📈Investments: gains and what it boughtinteractive

Loading the interactive chart…

🏭Its industry’s money flow (input-output)interactive

Loading the interactive chart…

About Nu Skin Enterprises

Nu Skin Enterprises Inc. (NYSE: NUS) is an intelligent beauty and wellness company, powered by a dynamic affiliate opportunity platform, which operates in nearly 50 markets worldwide. Backed by more than 40 years of scientific research, the company’s products help people look, feel and live their best with our newly introduced Prysm iO intelligent wellness platform, an award-winning line of beauty device systems and trusted brands in personal care and wellness products. Rhyz is the strategic investment arm of Nu Skin Enterprises, formed in 2018 consisting of synergistic consumer, technology and manufacturing companies focused on innovation within the beauty, wellness and lifestyle categories.

In its own words, from its 8-K, filed Aug 10, 2026.

Nu Skin Enterprises against its Wholesale-Drugs, Proprietaries & Druggists' Sundries peers

The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -15% against the peers' median +5%. Operating margin: 1.6% against the peers' median 1.3%.

CompanyQuarterRevenueY/YOp. margin
NUS Nu Skin EnterprisesQ3 2026$311M-15%1.6%
MCK McKessonQ2 FY27$111.0B+8%1.4%
COR CencoraQ3 FY26$84.8B+5%1.3%
CAH Cardinal HealthQ1 FY27$67.5B+6%1.1%
HLF HerbalifeQ3 2026$1.4B+6%10.3%
COSM Cosmos HealthQ2 2026$19.0M+29%-15.4%
MEDS DataMeds AIQ2 2026$1.8M-77%-412.7%
STEK StemtechQ2 2026$629K-10%-20.0%
ESYN HWH InternationalQ2 2026$64K-79%328.1%

Source: Nu Skin Enterprises 10-Q on SEC EDGAR · CIK 1021561 · Wholesale-Drugs, Proprietaries & Druggists' Sundries

Guidance and outlook

Nu Skin Enterprises Revenue: guidance against what was reportedNu Skin Enterprises Revenue: guidance against what was reportedguided rangereported (above / within / below)Q2 2026$320MQ4 2026
Met or beat 0 of 1 guided periods. Grey: the last range guided before the figures came out; dot: the reported figure.
Nu Skin Enterprises: what its forward-looking statements are about (10-Q filed 2026-11-06)Nu Skin Enterprises: what its forward-looking statements are about (10-Q filed 2026-11-06)Other3Capital spending1Buybacks & dividends1
5 statements; tone +0.00 (−1 all cautious, +1 all confident); 0 hedged.
Nu Skin Enterprises: outlook statements against the filing beforeNu Skin Enterprises: outlook statements against the filing beforeConfident1Cautious1

13F: who owns NUS and who is buying

Largest holders of NUS (13F)Largest holders of NUS (13F)Vanguard Group$41.7MBlackRock$22.8MAmerican Century Companies$12.2MCoppell Advisory Solutions LLC$11.3MVanguard Capital Management LLC$10.8MAcadian Asset Management LLC$10.3MDimensional Fund Advisors LP$9.5MVanguard Portfolio Management LLC$9.2MRenaissance Technologies LLC$8.5MCharles Schwab Investment Managem…$7.7M
Funds' net buying of NUS by quarter (13F)Funds' net buying of NUS by quarter (13F)$3.5M2024-09$6.7M2024-12−$10.8M2025-03−$2.2M2025-06−$25K2025-09$7.5M2025-12−$2.0M2026-03$1.4M2026-06
Value of shares 13F filers added minus the value they sold, each quarter (quarters with most filings in).

More on NUS

History

Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results

Compare NUS with

中文版：Nu Skin Enterprises（NUS）财报

Español · Français